Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Conversion therapy for advanced hepatocellular carcinoma following complete response to transarterial radioembolization combined with atezolizumab and bevacizumab
Authors:ID Popović, Peter, Clinical Institute of Radiology, University Medical Centre Ljubljana , Ljubljana , Slovenia Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia (Author)
ID Kalamutova, Ana, Department of Abdominal Surgery, University Medical Centre Ljubljana , Ljubljana , Slovenia (Author)
ID Djokić, Mihajlo, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia Department of Abdominal Surgery, University Medical Centre Ljubljana , Ljubljana , Slovenia (Author)
ID Cuderman, Anka, Department of Nuclear Medicine, University Medical Centre Ljubljana , Ljubljana , Slovenia (Author)
ID Boltezar, Gasper, Diagnostic Center Bled Group , Bled , Slovenia (Author)
ID Trotovsek, Blaz, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia Department of Abdominal Surgery, University Medical Centre Ljubljana , Ljubljana , Slovenia (Author)
Files:URL URL - Source URL, visit https://www.sciendo.com/pdf/10.2478/raon-2026-0015
 
.pdf PDF - Presentation file, download (670,04 KB)
MD5: 3EA8222D9FC0F0B6F93E8D187CFC51B6
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo DRO - Association of Radiology and Oncology
Abstract:Background: The current Barcelona Clinic Liver Cancer (BCLC) classification recommends systemic treatment with atezolizumab and bevacizumab as the first-line therapy for advanced hepatocellular carcinoma (HCC). Recent studies suggest that combining systemic immunotherapy with locoregional treatments, such as transarterial radioembolization (TARE), may enhance immune responses and improve overall treatment outcomes. This article presents a case series of three patients with advanced hepatocellular carcinoma who were treated with transarterial radioembolization followed by atezolizumab and bevacizumab achieving conversion to surgical resection. Patients and methods: Between June 2020 and April 2024, three patients with advanced HCC were treated with TARE followed by atezolizumab and bevacizumab. The cohort included: Patient 1: A 59-year-old female, with noncirrhotic liver, with a 12 cm tumor and a 1.5 cm satellite lesion located in the liver, with hepatic vein and inferior vena cava (IVC) tumor thrombosis (Vv3 Japanese classification) and a small lung metastasis. Patient 2: A 63-year-old male with chronic hepatitis C (CHV), presenting with a 10 cm tumor and portal vein tumor thrombosis (Vp4 Japanese classification). Patient 3: A 50-year-old male, with non-cirrhotic liver, with a 17 cm tumor with portal vein and IVC tumor thrombosis (Vp3, Vv3 Japanese classification). Results: The combined treatment approach enabled surgical resection in all three patients, each achieving a complete pathological response. Interestingly, follow-up dosimetric analysis showed that all tumors had received a subtherapeutic absorbed radiation doses. Conclusions: In selected patients, combining transarterial radioembolization with systemic immunotherapy may enable conversion to surgical resection in advanced hepatocellular carcinoma, even with subthreshold tumor radiation doses, highlighting a potential synergistic and abscopal effect between locoregional and systemic therapies.
Publication status:Published
Publication version:Version of Record
Publication date:01.03.2026
Publisher:Association of Radiology and Oncology
Number of pages:str. 40-48
Numbering:Vol. 60, no. 1
Source:Ljubljana
PID:20.500.12556/DiRROS-30283 New window
eISSN:1581-3207
DOI:10.2478/raon-2026-0015 New window
Publication date in DiRROS:18.06.2026
Views:44
Downloads:22
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Back